Subjects with a pathologic confirmation of the diagnosis of AML, ALL, or blast-phase CML

ECOG Performance Status 0-2

Adequate organ function as defined in the protocol.

Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

Hyperleukocytosis

Acute Promyelocytic Leukemia (FAB-M3) subtype

Uncontrolled Disseminated Intravascular Coagulation (DIC)

Active central nervous system leukemia

Concomitant radiation therapy, chemotherapy, or immunotherapy

Women who are pregnant or lactating

Neuropathy ≥ grade 2 (NCI CTCAE) at time of enrollment

Chemotherapy (with the exception of hydroxyurea) or radiotherapy within two weeks or within six times the agent's half life

Require ongoing therapy with either G- or GM-CSF, or long-acting versions of these molecules

Use of any investigational agents within two weeks or within six times the agent's half life --Treatment with chronic immunosuppressants

Other medical/psychiatric condition that may increase the risk associated with study participation as defined by the protocol.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00964873